Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


ARUP Named UCL Enterprise Partner of the Year 2010

20 May 2010

The important collaborative relationship with ARUP has now been recognised with an award for UCL Enterprise Partner of the Year 2010.